Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
Date:8/4/2008

SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview at the following investment conferences:

-- Bank of America's 2008 Specialty Pharmaceuticals Conference at the

Southampton Inn, Long Island, New York on Thursday, August 7, 2008 at

1:35pm Eastern Time (10:35am Pacific Time)

-- Canaccord Adams' 28th Annual Global Growth Conference at the

InterContinental Hotel in Boston on Tuesday, August 12 at 9:00am

Eastern Time (6:00am Pacific Time)

Each presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
2. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
3. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
5. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
6. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... in Australia through ... retail pharmacies nationwide, TAMPA, Fla., ... leader in pharmacy-based patient care services and,healthlinks.net, a subsidiary of ... a definitive technology licensing and business,consulting agreement, paving the way ...
... to receive funding for preclinical and clinical research projects ... ... ROCKLAND, Mass., Oct. 14 The Michael J. Fox Foundation,for ... five,research teams to speed development of effective therapies for the,under-addressed ...
... Logix, a privately held,biopharmaceutical company focused on using ... drugs, is pleased to announce the,appointment of Keith ... Chief,Executive Officer and to its Board of Directors. ... years of leadership experience in the,biotechnology industry., ...
Cached Biology Technology:Mirixa Announces Agreement With the Pharmacy Guild of Australia 2Mirixa Announces Agreement With the Pharmacy Guild of Australia 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 2Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 4Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 5Surface Logix Appoints Keith Dionne as President and Chief Executive Officer 2
(Date:4/16/2014)... A 20-year assessment of Nicaragua,s legal, artisanal green sea ... overall catch rates of turtles in what may have ... the Wildlife Conservation Society and University of Florida. , ... than 170,000 green turtles were killed between 1991 and ...
(Date:4/16/2014)... From far away, the top of a leaf looks ... exterior is actually made up of a patchwork of ... in how these cells individually take on their own ... Sampathkumar, and colleagues sought to pinpoint the shape-controlling factors ...
(Date:4/16/2014)... as Kennedy,s disease, spinal and bulbar muscular atrophy (SBMA) is ... weakness and atrophy. Researchers have long considered it to be ... in the spinal cord and brainstem that control muscle movement. ... 16, 2014 online issue of Neuron , a team ...
Breaking Biology News(10 mins):Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3For cells, internal stress leads to unique shapes 2Mutant protein in muscle linked to neuromuscular disorder 2
... We all know that iron deficiencies are dangerous, but ... Our body stores excess iron in various tissues, where ... if not treated before irreversible damage has occurred. Researchers ... Germany, and the European Molecular Biology Laboratory (EMBL) now ...
... discovered the stage at which some of the cells of ... cells and why this occurs. The findings of the ... same until the fourth cleavage (division) of the embryo, are ... the cells of the embryo at first undergo equal, symmetrical ...
... of Ebola virus killed tens of thousands of gorillas ... the May issue of The American Naturalist provide new ... transmission between ape social groups. The study provides hope ... of Ebola on wild apes. , Direct encounters ...
Cached Biology News:Putting an old drug to a new use 2Scientists discover stage at which an embryonic cell is fated to become a stem cell 2Ebola outbreaks killing thousands of gorillas and chimpanzees 2
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
... AmpliTaq Gold® DNA Polymerase is a chemically ... the chemical moiety is attached to the ... and the first ramp of thermal cycling ... annealing temperatures), the enzyme is inactive. The ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Ps-Aeruginosa (IgG) -Ab EIA Sample Size: 100 l...
Biology Products: